This review examines the evolution of intravenous (IV) iron therapies, focusing on newer formulations such as ferumoxytol, ferric carboxymaltose, and iron isomaltoside. These agents possess more stable iron-carbohydrate complexes, allowing for higher single-dose administrations with reduced labile iron release, thereby minimizing infusion-related adverse events. Their enhanced safety profiles and dosing
This review discusses the clinical experience with intravenous ferric carboxymaltose (FCM) for treating iron deficiency anemia (IDA) in adults intolerant to or unresponsive to oral iron, or with nondialysis-dependent chronic kidney disease. FCM allows administration of up to 750 mg per dose (totaling 1500 mg over two doses), delivered over
This randomized, multicenter, double-blind clinical trial assessed the safety and efficacy of intravenous ferumoxytol compared to ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) unresponsive or intolerant to oral iron. A total of 1,997 patients received either ferumoxytol (n=997) or FCM (n=1000) over ≥15 minutes on days 1
This review article redefines iron deficiency in patients with chronic heart failure (CHF), arguing that current diagnostic criteria based on serum ferritin and transferrin saturation may miss cases of functional iron deficiency at the tissue level. It emphasizes the importance of intracellular iron for mitochondrial function and energy production in
